VILLA, MATTEO
 Distribuzione geografica
Continente #
AS - Asia 2.103
NA - Nord America 1.834
EU - Europa 1.635
SA - Sud America 338
AF - Africa 56
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.979
Nazione #
US - Stati Uniti d'America 1.758
IT - Italia 735
SG - Singapore 622
VN - Vietnam 478
CN - Cina 417
BR - Brasile 265
HK - Hong Kong 223
RU - Federazione Russa 194
DE - Germania 156
FR - Francia 93
IE - Irlanda 78
GB - Regno Unito 70
IN - India 66
SE - Svezia 62
KR - Corea 55
ID - Indonesia 47
CA - Canada 43
BD - Bangladesh 42
FI - Finlandia 41
NL - Olanda 36
ES - Italia 33
CH - Svizzera 28
PL - Polonia 28
AT - Austria 26
AR - Argentina 25
TR - Turchia 22
JP - Giappone 20
MX - Messico 18
PH - Filippine 18
ZA - Sudafrica 18
IQ - Iraq 15
EC - Ecuador 14
UA - Ucraina 13
PK - Pakistan 12
LT - Lituania 11
MA - Marocco 11
SA - Arabia Saudita 10
UZ - Uzbekistan 10
VE - Venezuela 9
AU - Australia 8
KE - Kenya 8
PE - Perù 8
BE - Belgio 7
CL - Cile 7
TH - Thailandia 6
EG - Egitto 5
IR - Iran 5
MY - Malesia 5
RO - Romania 5
CR - Costa Rica 4
JO - Giordania 4
NP - Nepal 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
CO - Colombia 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
OM - Oman 3
PY - Paraguay 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
MK - Macedonia 2
RS - Serbia 2
SV - El Salvador 2
TN - Tunisia 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
GR - Grecia 1
KG - Kirghizistan 1
LB - Libano 1
LC - Santa Lucia 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MT - Malta 1
NG - Nigeria 1
NI - Nicaragua 1
PA - Panama 1
PR - Porto Rico 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
TO - Tonga 1
TT - Trinidad e Tobago 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.979
Città #
Singapore 343
Ashburn 278
Milan 272
San Jose 223
Hong Kong 207
Dallas 187
Ho Chi Minh City 143
Hanoi 137
Hefei 100
Ann Arbor 96
Los Angeles 89
New York 86
Frankfurt am Main 79
Dublin 76
Beijing 62
Seoul 51
Chicago 40
Santa Clara 40
Jakarta 37
The Dalles 37
Munich 35
Chandler 33
São Paulo 29
Council Bluffs 26
Lauterbourg 26
Moscow 25
Buffalo 24
Desio 24
Zurich 23
Rome 22
Seveso 21
Toronto 21
Fairfield 20
Helsinki 20
Kent 19
Tokyo 18
Warsaw 18
Monza 17
Da Nang 16
London 16
Turku 16
Carate Brianza 15
Chennai 15
Haiphong 15
Stockholm 15
Houston 14
Nuremberg 14
Orem 14
Montreal 13
Denver 12
Poplar 12
Shanghai 12
Vienna 12
Amsterdam 11
Atlanta 11
Johannesburg 11
Rio de Janeiro 11
Genoa 10
Ha Long 10
Lissone 10
Paris 10
Phoenix 10
Tashkent 10
Perugia 9
Ankara 8
Biên Hòa 8
Can Tho 8
Lima 8
Manchester 8
Quezon City 8
Turin 8
Boston 7
Brooklyn 7
Brussels 7
Campinas 7
Cesano Maderno 7
Ithaca 7
Pune 7
Quận Bình Thạnh 7
Quận Một 7
San Diego 7
Seattle 7
Seregno 7
Sesto San Giovanni 7
Wilmington 7
Baghdad 6
Corsico 6
Curitiba 6
Lodz 6
Magenta 6
Nairobi 6
Princeton 6
Querétaro 6
Romola 6
Brescia 5
Florence 5
Hải Dương 5
Istanbul 5
Jeddah 5
Lappeenranta 5
Totale 3.566
Nome #
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 424
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 396
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 349
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 335
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 322
Investigation of drug resistance and co-mutational landscape of ALK-positive tumors 321
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 302
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 282
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 279
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 277
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 271
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 267
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 254
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 252
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 245
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 234
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 226
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 222
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 195
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 187
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 183
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 146
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) 105
Totale 6.074
Categoria #
all - tutte 16.877
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.877


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 0 6 6
2021/202269 5 6 4 4 10 5 8 3 7 6 3 8
2022/2023221 20 34 17 17 8 15 1 9 20 33 22 25
2023/2024477 41 22 22 20 59 94 73 16 34 23 30 43
2024/20251.551 52 94 88 78 105 58 98 43 181 255 156 343
2025/20263.613 485 322 402 496 365 182 517 148 255 350 91 0
Totale 6.074